| # | Drug | Count |
|---|---|---|
| 0 | OXALIPLATIN | 38 |
| 1 | CAPECITABINE | 14 |
| 2 | QUETIAPINE | 7 |
| 3 | FLUOROURACIL | 5 |
| 4 | FLUOROURACIL CREAM, 0.5% | 5 |
| 5 | CYCLOPHOSPHAMIDE | 4 |
| 6 | CYCLOPHOSPHAMIDE FOR INJECTION | 4 |
| 7 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 4 |
| 8 | FAM-TRASTUZUMAB DERUXTECAN-NXKI | 4 |
| 9 | AZATHIOPRINE | 3 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | TERLIPRESSIN | 2 | 0.0060 |
| 1 | BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE | 1 | 0.0009 |
| 2 | OXALIPLATIN | 38 | 0.0005 |
| 3 | DACARBAZINE | 3 | 0.0004 |
| 4 | FAM-TRASTUZUMAB DERUXTECAN-NXKI | 4 | 0.0004 |
| 5 | IMMUNE GLOBULIN INFUSION (HUMAN), 10% WITH RECOMBINANT HUMAN HYALURONIDASE | 1 | 0.0002 |
| 6 | ALBUMIN HUMAN | 1 | 0.0002 |
| 7 | STERILE WATER FOR INJECTION | 1 | 0.0002 |
| 8 | ALBUMIN (HUMAN) | 1 | 0.0002 |
| 9 | CAPECITABINE | 14 | 0.0002 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 38 |
| 1 | Nucleoside Metabolic Inhibitor [EPC] | 19 |
| 2 | Atypical Antipsychotic [EPC] | 7 |
| 3 | Alkylating Drug [EPC] | 4 |
| 4 | Corticosteroid [EPC] | 3 |
| 5 | Purine Antimetabolite [EPC] | 3 |
| 6 | Antimetabolite [EPC] | 2 |
| 7 | CD20-directed Cytolytic Antibody [EPC] | 2 |
| 8 | Catecholamine [EPC] | 2 |
| 9 | alpha-Adrenergic Agonist [EPC] | 2 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Platinum-based Drug [EPC] | 38 | 0.0001 |
| 1 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 19 | 0.0001 |
| 3 | Human Immunoglobulin G [EPC] | 1 | 0.0000 |
| 4 | Antimetabolite Immunosuppressant [EPC] | 1 | 0.0000 |
| 5 | Purine Antimetabolite [EPC] | 3 | 0.0000 |
| 6 | Estrogen Receptor Antagonist [EPC] | 1 | 0.0000 |
| 7 | Catecholamine [EPC] | 2 | 0.0000 |
| 8 | Alkylating Drug [EPC] | 4 | 0.0000 |
| 9 | Cholinergic Nicotinic Agonist [EPC] | 1 | 0.0000 |